Polymeric nanoparticles - Targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities

Endocrine Regulations

Volumn 45, Issue 1, 2011, Pages 49-60

  Rollerova, E ^a   Scsukova, S ^b   Jurcovicova, J ^b   Mlynarcikova, A ^b   Szabova, E ^a   Kovriznych, J ^a   Zeljenkova, D ^a  

^a SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Endocrine disruption; KiSS 1 system; Nanomaterials; Nanotoxicology; Polyethylene glycol; Polymeric nanoparticles; Reproduction; Review

Indexed keywords

ENDOCRINE DISRUPTOR; NANOPARTICLE; POLYMERIC NANOPARTICLE; UNCLASSIFIED DRUG; POLYMER;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DELIVERY SYSTEM; GENITAL SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NANOTOXICOLOGY; NEUROENDOCRINE SYSTEM; REVIEW; DRUG EFFECT; METHODOLOGY; NEUROSECRETION;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEUROSECRETORY SYSTEMS; POLYMERS;

EID: 79959643676     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2011_01_49     Document Type: Review

References (72)

1. Avgoustakis K: Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv 1, 321-333, 2004. doi:10.2174/1567201043334605
2. Baker VA: Endocrine disrupters-testing strategies to assess human hazard. Toxicol in Vitro 15, 4-5, 2001. doi:10.1016/S0887-2333(01)00045-5
3. Balbus JM, Maynard AD, Colvin L, Castranova V, Datson GP, Denison RA, Dreher K L, Goering PL, Goldberg AM, Kulinowski KM, Monteiro-Riviere NA, Oberdörster G, Omenn GS, Pinkerton KE, Ramos KS, Rest KM, Sass JB, Silbergeld EK, Wong BA: Meeting Report: Hazard assessment for nanoparticles report from an interdisciplinary workshop. Environ Health Perspect 115, 1664-1669, 2007. doi:10.1289/ehp.10327
4. Beduneau A, Saulnier P, Benoit J-P: Active targeting of brain tumours using nanocarriers. Biomaterails 28, 4947-4967, 2007. doi:10.1016/j.biomaterials.2007.06.011
5. Bellingham M, Fowler PA, Amezaga MR, Rhind SM, Cotinot C, Mandon-Pepin B, Sharpe RM, Evans NP: Exposure to a complex cocktail of environmental endocrine-disrupting compounds disturbs the kisspeptin/GPR45 system in ovine hypothalamus and pituitary gland. Environ Health Perspect 117, 1556-1562, 2009.
6. Bondioli L, Constantino L, Ballestrazzi A, Lucchesi D, Boraschi D, Pellati F, Benvenuti S, Tosi G, Vandelli MA: PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 31,3395-3403,2010. doi:10.1016/j.biomaterials.2010.01.049
7. Borm PJA, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K, Schins R, Stone V, Kreyling W, Lademann J, Krutmann J, Warheit D, Oberdörster E: The potential risks of nanomaterials: a review carried out for ECETOC. Particle and Fibre Toxicol 3, 11-43, 2006. doi:10.1186/1743-8977-3-11
8. Buck Louis GM, Lynch CD, Cooney MA: Environmental influences on female fecundity and fertility. Semin Reprod Med 24, 147-155, 2006. doi:10.1055/s-2006-944421
9. Chan Y-M, Broder-Fingert S, Seminara SB: Reproductive functions of kisspeptin and Gpr54 across the life cycle of mice and men. Peptides 30, 42-48, 2009. doi:10.1016/j.peptides.2008.06.015
10. Colborn T, vom Saal FS, Soto AM: Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 101, 378-384, 1993. doi:10.2307/3431890
11. Colledge WH, d'Anglemont de Tassigny X: The role of kisspeptin signalling in the regulation of the GnRH-gonadotrophin ovarian axis in mice. Ann Endocrinol (Paris), Ann Edocrinol(Paris) 71,198-200-2010. doi:10.1016/j.ando.2010.02.011
12. Constantino L, Gandolfi G, Tosi G, Rivasi F, Vandelli MA, Forni F: Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control Release 108, 84-96, 2005. doi:10.1016/j.jconrel.2005.07.013
13. De Jong WH, Borm PJA: Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 3, 133-149, 2008. doi:10.2147/IJN.S596
14. Dickerson SM, Gore AC: Estrogenic environmental endocrine-disrupting chemical effects on reproductive neuroendocrine function and dysfunction across the life cycle. Rev Endocr Metab Disord 8, 143-159, 2007. doi:10.1007/s11154-007-9048-y
15. Dreher KL: Health and environmental impact of nanotechnology: Toxicological assessment of manufactured nanoparticles. Toxicol Sci: 77, 3-5, 2004. doi:10.1093/toxsci/kfh041
16. Drobne D: Nanotoxicology for safe and sustainable nanotechnology. Arh Hig Rada Toksikol 58, 471-478, 2007. doi:10.2478/v10004-007-0040-4
17. Fernandez C, Soni U, Patravale V: Nano-interventions for neurodegenerative disorders. Pharmacol Res 62, 166-178, 2010. doi:10.1016/j.phrs.2010.02.004
18. Gajdova M, Jakubovsky J, Valky J: Delayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats. Fd Chem Toxic 31, 183-190, 1993. doi:10.1016/0278-6915(93)90092-D
19. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu Sh: Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 27, 3482-3490, 2006. doi:10.1016/j.biomaterials.2006.01.038
20. Gore AC, Heindel JJ, Zoeller RT: Endocrine disruption for endocrinologists (and others). Endocrinology 147, S1-S3, 2006. doi:10.1210/en.2005-1367
21. Gore AC: Is reproductive ageing controlled by the brain? Neuroendocrinol. Briefing 28, 667-668, 2007. doi:10.1111/j.1365-2826.2007.01573.x
22. Gore AC: Developmental programming and endocrine disruptor effects on reproductive neuroendocrine systems. Frontiers in Neuroendocrinol 29, 358-374, 2008. doi:10.1016/j.yfrne.2008.02.002
23. Hagens WI, Oomen AG, de Jong WH, Cassee S F.R., Sips AJAM: What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49, 217-229, 2007. doi:10.1016/j.yrtph.2007.07.006
24. Halmos T, Santarromana M, Herscovici J, Scherman D: Brain drug delivery through the blood-brain barrier transport systems. Attempted strategies and issues. STP Pharma Sci 7, 37-42, 1997.
25. Henley DV, Korach KS: Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. Endocrinology 147, S25-S32, 2006. doi:10.1210/en.2005-1117
26. Holsapple MP, Farland WH, Landry TD, Monteiro-Riviere NA, Carter JM, Walker NJ, Thomas KV: Research strategies for safety evaluation of nanomaterials, Part II: Toxicological and safety evaluation of nanomaterials, current challenges and data needs. Toxicol Sci 88, 12-17, 2005. doi:10.1093/toxsci/kfi293
27. Hotckiss AK, Rider CV, Blystone CR, Wilson VS, Hartig PC, Ankley GT, Foster P M, Gray CL, Gray LE: Fifteen years after "Wingspread"-Environmetnal Endocrine Disrupters and human and wildlife health: Where we are today and where we need to go. Toxicol Sci 105, 235-259, 2008. doi:10.1093/toxsci/kfn030
28. Kateb B, Chiu K, Black KL, Zamamoto V, Khalsa B, Ljubimova JY, Ding H, Patil R, Portilla-Arias JA, Modo M, Moore DF, Farahani K, Okun MS, Prakash N, Neman J, Ahdoot D, Grundfest W, Nikzad S, Heiss JD: Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? Neuroimage 54, Suppl. 1, 5106-5124, 2011 Neuroimage. doi:10.1016/j.neuroimage.2010.01.105
29. Kauffman AS: Sexual differentiation and the Kiss1 system: Hormonal and developmental consideration. Peptides 30, 83-93, 2009. doi:10.1016/j.peptides.2008.06.014
30. Kouki T, Kishitake M, Okamoto M, Oosuka I, Takebe M, Yamanouchi K: Effects of neonatal treatment with phytoestrogens, genistein and daidzein, on sex difference in female rat brain function: estrous cycle and lordosis. Hormones and Behaviour 44, 140-145, 2003. doi:10.1016/S0018-506X(03)00122-3
31. Lehman MN, Merkley ChM, Coolen LM, Goodman RL: Anatomy of the kisspeptin neural network in mammals. Brain Research 1364,90-102, 2010. doi:10.1016/j.brainres.2010.09.020
32. Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 4, 26-49, 2008. doi:10.1002/smll.200700595
33. Marquis BJ, Love SA, Braun KL, Haynes ChL: Analytical methods to assess nanoparticle toxicity. Analyst 134, 425-439, 2009. doi:10.1039/b818082b
34. Millar RP, Roseweir AK, Tello JA, Anderson RA, George JT, Morgan K, Pawson AJ: Kisspeptin antagonists: Unraveling the role of kisspeptin in reproductive physiology. Brain Res 1364, 90-102, 2010. doi:10.1016/j.brainres.2010.09.044
35. Moore CR and Price D: Gonadal hormone functions and the reciprocal influence between gonads and hypophysis, with its bearing on sex hormone antagonism. Am J Anat 50,13-71, 1932. doi:10.1002/aja.1000500103
36. Navarro VM, Fernandez-Fernandez R, Castellano JM, Roa J, Mayen A, Barreiro ML, Gaytan F, Aguilar E, Pinilla L, Dieguez C, Tena-Sempere M: Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. J Physiol 561.2, 379-386, 2001. doi:10.1113/jphysiol.2004.072298
37. Navarro VM, Castellano JM, Fernandez-Fernandez R, Barreiro ML, Roa J, Sanchez-Criado JE, Aguilar E, Dieguez C, Pinilla L, Tena-Sempere M: Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology 145, 4565-4574, 2004. doi:10.1210/en.2004-0413
38. Navarro VM and Tena-Sempere M: The Kiss-1/GPR54 system: putative target for endocrine disruption of reproduction at hypothalamic-adenopituitary unit? Int J Androl 31, 224-232, 2008. doi:10.1111/j.1365-2605.2007.00833.x
39. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, Katayama Y, Niidomo Y: PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 114, 343-347, 2006. doi:10.1016/j.jconrel.2006.06.017
40. Oberdörster G: Safety assessment for nanotechnology and nanomedicine: concepts of toxicology. J Intern Med 267, 89-105, 2010. doi:10.1111/j.1365-2796.2009.02187.x
41. Olivier JCh: Drug transport to brain with targeted nanoparticles. J Am Soc Exp NeuroTherapeutics 2, 108-119, 2005.
42. Owens DE, Peppas NA: Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307, 93-102, 2006. doi:10.1016/j.ijpharm.2005.10.010
43. Partridge WM: Drug targeting to the brain. Pharm Res 24, 1733-1744, 2007. doi:10.1007/s11095-007-9324-2
44. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF: Getting into the brain. CNS Drugs 23, 35-58, 2009. doi:10.2165/0023210-200923010-00003
45. Pelham RW, Nix LC, Chavira RE, Cleveland MVB, Stetson P: Clinical trial: single-and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in young and elderly subjects. Aliment Pharmacol Ther 25, 256-265, 2008. doi:10.1111/j.1365-2036.2008.03727.x
46. Plard J-P, Bazile D: Comparison of the safety profiles of PLA50 and Me. PEG-PLA50 nanopartilces after single dose intravenous administration to rat. Colloids and Surfaces B: Biointerfaces 16,173-183,1999. doi:10.1016/S0927-7765(99)00068-5
47. Powers KW, Brown SC, Krishna VB, Wasdo SC, Moudgil BM, Roberts SM: Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation. Toxicol Sci 90, 296-303, 2006. doi:10.1093/toxsci/kfj099
48. Randall JM: In: Nanotechnology for Cancer Therapy, (Ed. Mansoor MA), pp.19-42, CRC Press, Boca Raton 2007.
49. Ricci M, Blasi P, Giovagnoli S, Rossi C: Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chemistry 13, 1757-1775, 2006. doi:10.2174/092986706777452461
50. Roseweir AK, Millar RP: The role of kisspeptin in the control of gonadotropin secretion. Human Reprod Update 15, 203-212, 2009. doi:10.1093/humupd/dmn058
51. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ: Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 5,371-383, 2008.
52. Schoeters G, Den Hond E, Dhooge W, van Larebeke N, Leijs M: Endocrine disruptors and abnormalities of pubertal development. Basic & Clin Pharmacol & Toxicol 102, 168-175, 2008. doi:10.1111/j.1742-7843.2007.00180.x
53. Smith JT: Kisspeptin signaling in the brain: steroid regulation in the rodent and ewe. Brain Research Review 57, 288-298, 2008. doi:10.1016/j.brainresrev.2007.04.002
54. Suh J, Choy K-L, Lai SK, Suk JS, Tang BC, Prabhu S, Hanes J: PEGylation of nanoparticles improves their cytoplasmic transport. Inter J Nanomed 2, 735-741, 2007.
55. Suh WH, Suslick KS, Stucky GD, Suh Y-H: Nanotechnology, nanotoxicology, and neuroscience. Progress in Neurobiology 87, 133-170, 2009. doi:10.1016/j.pneurobio.2008.09.009
56. Tena-Sempere M, Barreiro ML, Aguilar E, Pinilla L: Mechanisms for altered reproductive function in female rats following neonatal administration of raloxifene. Europ J Endocrinol 150, 397-403, 2004. doi:10.1530/eje.0.1500397
57. Tena-Sempere M: Kisspeptin/GPR54 system as potential target for endocrine disruption of reproductive development and function. Int J Androl 33, 360-368, 2009. doi:10.1111/j.1365-2605.2009.01012.x
58. Tena-Sempere M: Kisspeptin signaling in the brain: Recent developments and future challenges. Mol Cell Endocrinol 314, 164-169, 2010. doi:10.1016/j.mce.2009.05.004
59. Tiwari SB and Amiji MM: A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3, 219-232, 2006. doi:10.2174/156720106776359230
60. Tosi G, Constantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandeli MA, Forni F: Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Lorepamide and Rhodamine-123. J Control Release 122,1-9, 2007. doi:10.1016/j.jconrel.2007.05.022
61. Tosi G, Constantino L, Ruozi B, Forni F, Vandelli MA: Polymeric nanoparticles for the drug delivery to central nervous system. Expert Opin Drug Deliv 5, 155-174, 2008. doi:10.1517/17425247.5.2.155
62. Tosi G, Vergoni AV, Ruozi B, Bondoli L, Badiali L, Rivasi F, Constantino L, Forni F, Vandelli MA: Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release, 145, 49-57, 2010. doi:10.1016/j.jconrel.2010.03.008
63. Tsuji JS, Maynard AD, Howard PC, James JT, Lam Ch-W, Warheit DB, Santamaria AB: Research strategies for safety of nanomaterials, part IV: Risk assessment of nanoparticles. Toxicol Sciences 89, 42-50, 2006. doi:10.1093/toxsci/kfi339
64. US EPA Nanotechnology White Paper Science Policy Council, Nanotechnology Workshop, Report No: EPA 100-B-07-001, 132 pp, Feb 2007. Available at http://es.epa.gov/ncer/nano/publications/whitepaper12022005.pdf
65. Utsuyama M, Kanno J, Inoue T, Hirokawa K: Age/sex dependent and non-monotonous dose-response effect of diethylstilbestrol on the immune functions in mice. Toxicol Letters 135, 145-153, 2002. doi:10.1016/S0378-4274(02)00256-4
66. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Constantino L: Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine: NBM 5, 369-377, 2009.
67. Wang J, Sui M, Fan W: Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11, 129-141, 2010. doi:10.2174/138920010791110827
68. West A, Vojta PJ, Welsch DR, Weissman BE: Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KiSS1). Genomics 54, 145-148, 1998. doi:10.1006/geno.1998.5566
69. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K: Long-circulation poly(ethylene glycol)-poly(-lactide) block copolymer micelles with modulated surface charge. J Control Release 77, 27-38, 2001. doi:10.1016/S0168-3659(01)00451-5
70. Yang X, Zhu B, Dong T, Pan P, Shuai X, Inoue Y: Interactions between an anticancer drug and polymeric micelles based on biodegradable polyesters. Macromol Biosci 8, 1116-1125, 2008. doi:10.1002/mabi.200800085
71. Yoshida S, Hiyoshi K, Ichinose T, Takano H, Oshio S, Sugawara I, Takeda K, Shibamoto T: Effect of nanoparticles on the male reproductive system of mice. Int J Androl 32, 337-342, 2009.
72. Zolnik BS, Gonzales-Fernandez A, Sadrieh N, Dobrovolskaia MA: Nanoparticles and the immune system. Endocrinology 151, 458-465, 2010. doi:10.1210/en.2009-1082